Lonitoclax
Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas[1].
Product Specifications
CAS Number
2952589-57-8
UNSPSC
12352005
Target
Bcl-2 Family
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(N1[C@@H](CC2=CC=CC=C2C1)CN3CCOCC3)C4=C(C5=CC(C(N(C6=CC=C(C=C6)O)CC7=C(C(OC)=CC=C7)C)=O)=C(N5C)C)C=C(C=C4)Cl
Molecular Formula
C43H45ClN4O5
Molecular Weight
733.29
References & Citations
[1]Dr. Iain Dukes, et al. FDA Clears Lomond Therapeutics' IND for Phase 1 Study of Lonitoclax in CLL, SLL, and Low-Grade Lymphomas. 1 November 2024.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (B-K9), CF594 conjugate, 0.1mg/mL
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
Complement C4d (C4D204), CF405S conjugate, 0.1mg/mL
